The Business Impact of EUDAMED on Market Access

The European Database on Medical Devices (EUDAMED) is often viewed by manufacturers purely as a compliance burden when trying to gain market access. EUDAMED is a database requiring mandatory data sets with compliance obligations under the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) and it is important for manufacturers to understand how to navigate the database. However, this perspective overlooks the profound business implications of the system. EUDAMED is not merely a database to be used by economic operators; it is the central data repository of the European Union used by Competent Authorities as a fundamental tool for market surveillance. As mandatory deadlines approach in 2026, the data within EUDAMED will determine market access, influence procurement decisions, and influence the speed of market entry.  

Approaching EUDAMED Deadlines 

For decades, the EU medical device market operated on a fragmented system of national registrations and decentralized data (e.g. Italian Ministry of Health medical device database). The EU MDR and IVDR have fundamentally shifted this paradigm with the introduction of EUDAMED. Designed to enhance transparency and traceability, EUDAMED consolidates information on the following: 

• Actors  

• Devices (Unique Device Identification (UDI)) 

• Certificates 

• Clinical Investigations / Performance Studies 

• Vigilance & Post-Market Surveillance 

• Market surveillance into a single, accessible portal. 

While a simultaneous launch of all modules was originally intended, the publication of Regulation (EU) 2024/1860 legally enabled the progressive, module-by-module roll-out of EUDAMED and established the statutory rule that obligations related to a specific module apply six months after its functionality notice is published. The publication of Commission Decision (EU) 2025/2371 on 27 November 2025, as the official legal notice confirming that the Actor, UDI/Device, Certificate, and Marker Surveillance, triggered the 6-month countdown to mandatory use of these modules which ends on 28 May 2026. 

Based upon the European Commission’s most recent roadmap updates, the formal notice of the Vigilance & Post-Market Surveillance module is anticipated in late 2026, leading to expected mandatory use by around Q2 2027. Analysis and development of the Clinical Investigation / Performance Studies module is ongoing and expected to continue into 2027 according to this same roadmap update. 

With 28 May 2026 fast approaching, the era of voluntary submission is ending. 

This article analyzes five critical areas where EUDAMED impacts the bottom line:  

• The financial cost of non-compliance 

• The acceleration of time-to-market 

• The competitive edge of data quality 

• Te necessity of early preparation 

• The strategic value of an experienced EU Authorized Representative 

1. Financial Implications of Non-Compliance 

The most direct impact of gaining EUDAMED Market Access is the financial implications. Historically, non-compliance with administrative requirements might have resulted in private administrative correspondence or minor fines while sales continued, with public notices generally reserved for sever public health risks, fraud, or formal market suspension. For example, the French Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), arguably the most transparent Competent Authority in the EU regarding enforcement, has very little publicly available information on such instances of administrative non-compliance. Under the EUDAMED framework, the consequences are immediate and revenue threatening. 

Supply Chain Implications when Gaining EUDAMED Market Access

EUDAMED introduces a “hard stop” mechanism into the supply chain. Importers (under MDR/IVDR Article 13(4)) and EC-REPs (under MDR/IVDR Article 11(3)) are now legally obligated to verify that a device is correctly registered in EUDAMED before they place it on the market. Furthermore, the EU Authorized Representative must also ensure that the foreign device manufacturer has also registered in EUDAMED (under MDR/IVDR Article 11(3)). 

Under Articles 13 and 14 of the MDR/IVDR, both importers and distributors must respectively not place on the market or make available on the market any devices for which they consider or have reason to believe are not in conformity with the requirements of these regulations, and must inform the other economic operators in the supply chain of this non-compliance. Such non-compliance includes the lack of appropriate registration in EUDAMED. 

Subsequently, if a foreign manufacturer fails to obtain a Single Registration Number (SRN) for itself (generated through EUDAMED Actor registration) or fails to register a device, upon verification, importers and distributors may impede downstream product supply, resulting in: 

• Revenue Stoppage: Unlike a post-market recall which affects specific batches, EUDAMED non-compliance blocks product supply based upon importer / distributor compliance actions, resulting in lost revenue until resolved. 

• Stock Obsolescence: Devices sitting in customs or distribution warehouses cannot be cleared for sale due to lack of EUDAMED registration. This impacts inventory turnover ratios and can lead to write-offs for perishable products, particularly for IVDs with shorter shelf lives. 

Penalties and Market Surveillance

Because EUDAMED is built on the European Commission’s Connecting Europe Facility (CEF) eDelivery network (specifically using AS4 communication protocol), it shares a technical foundation with other major European digital infrastructure (e.g. EU Single Window Environment for Customs (EU-SWE-C)). Subsequently, Competent Authorities in EU Member States are increasingly using automated tools to cross-reference EUDAMED data with national customs and healthcare systems. Discrepancies trigger audits which may result in: 

• Direct Fines: Member States have established penalties for MDR/IVDR infringements. These can range from administrative fines to criminal sanctions depending on the severity and national law. For example, the following establish administrative fines for documentation failures (including registration failures) under the MDR/IVDR: 

• Germany: Medizinprodukterecht-Durchführungsgesetz (MPDG) 

Failure to register or submit required regulatory notifications is typically treated as an administrative offense (Ordnungswidrigkeit). Under the Section 94 of the MPDG, failing to fulfill European registration, notification, or data-sharing obligations is punishable by administrative fines of up to €30,000 per infraction. If the failure to register in EUDAMED is not just an administrative oversight, but part of a larger violation where an unassessed, unsafe device is deliberately placed on the market, German authorities will escalate the offense to criminal prosecution under Sections 92 and 93, which carries the risk of multi-year prison sentences. 

• Italy: Legislative Decree No. 137/2022 and Legislative Decree No. 138/2022 

If a manufacturer fails to comply with their general obligations under Article 10 of the MDR—which explicitly includes the mandate to register the economic operator, the PRRC, and the device in EUDAMED—they are subject to administrative fines ranging from €20,000 to €120,000. Importers and distributors also face their own parallel fines if they have failed to fulfill their obligations when accessing the EUDAMED market,

• France: Code de la santé publique (Public Health Code) 

For regulatory non-compliance, including the failure to register devices or economic operators, ANSM can leverage administrative financial penalties under provisions like Article L. 5461-9 of the Public Health Code. These fines can reach up to 30% of the turnover generated by the specific unregistered product, or up to 10% of the company’s total annual turnover (generally capped at €1,000,000 for purely administrative sanctions). If the failure to register is accompanied by deception—such as fraudulently claiming the device is compliant and placing it on the French market—the infringement becomes a criminal offense. Criminal fines for such acts can reach up to €1,875,000, alongside potential prison time for company executives. 

• Remediation Costs: The cost of fixing bad data is generally higher than getting it right the first time. Remediation may involve halting shipments, hiring external consultants at expedited rates, and correcting data fields while under regulatory scrutiny. 

Reputational Devaluation  

EUDAMED creates a public record of a manufacturer’s compliance status. Repeated delays, vigilance reports inconsistent with device registration, or suspended certificates are visible to Competent Authorities and, partly, to the public. This visibility directly impacts company valuation, particularly during mergers and acquisitions where due diligence typically includes a review of compliance data sources, such as that contained in EUDAMED. 

2. Facilitation of Time-to-Market through Data Readiness 

While often seen as a bottleneck, EUDAMED can facilitate time-to-market for manufacturers who treat data readiness as a core operational capability rather than an afterthought. 

Impact on Conformity Assessment

Notified Bodies (NBs) are under increased scrutiny and face resource constraints. Depending upon device classification, a manufacturer’s interaction with their NB is heavily mediated through EUDAMED. 

• Impact on Individual Reviews: When a manufacturer submits a technical file, the NB checks the corresponding data in EUDAMED. If the Basic UDI-DI data, risk classification, and certificate linkages align with the data in the technical file, relevant findings are not flagged by the NB, and the technical file review phase is facilitated. 

• Impact on Rounds of Review: Inaccurate or incomplete data triggers rounds of questions from the NB. Depending upon the NB’s resources and certification pipeline volume, each round of review adds weeks or months to the certification timeline. Ensuring alignment of the technical file with EUDAMED data allows the NB to focus on more technical (and/or clinical) elements of the review rather than administrative errors. 

Automating the Supply Chain 

EUDAMED data is not just for Competent Authorities; it provides public access to master data for economic operators in the European supply chain. 

• Distributor Onboarding: Manufacturers with EUDAMED-ready data can provide distributors with the necessary regulatory proof (SRN, UDI-DI) to clear compliance checks. This allows for faster onboarding of new distributors in new Member States. 

• Tender Readiness: Hospital procurement systems are increasingly integrating with EUDAMED to validate product eligibility (e.g. The central public purchasing network for French hospitals, eCat-Santé, is the most comprehensive real-world example of such integration). If a manufacturer’s data is in EUDAMED, they can use this data to bid on tenders. Competitors without EUDAMED registration will need to register prior to bidding on such time-sensitive opportunities. 

Global Harmonization Potential 

While EUDAMED is specific to the EU, the data model is largely based on IMDRF (International Medical Device Regulators Forum) principles, such as those established under IMDRF/UDI WG/N7FINAL:2013 and IMDRF/UDI WG/N48 FINAL:2019. Investing in the data architecture for EUDAMED streamlines compliance for other UDI-based markets like the US (GUDID), China, and South Korea. This “build once, deploy everywhere” approach reduces the marginal cost of entering new international markets. 

3. Competitive Advantage of High-Quality Device Data 

EUDAMED makes a subset of device data publicly available, transforming it into a competitive asset. 

Trust and Transparency 

As illustrated in the EU-funded Horizon Europe Improving Digital Empowerment for Active Health Living (IDEAHL) initiative, healthcare professionals (HCPs) and patients are becoming more data-savvy. EUDAMED allows the public to view the Summary of Safety and Clinical Performance (SSCP) / Summary of Safety and Performance (SSP) for high-risk medical devices and IVDs. 

• Building Trust: A manufacturer that provides clear, comprehensive, and well-written SSCPs / SSPs builds trust. It signals confidence in the product’s safety profile.  

• Procurement Preference: Hospital procurement officers prefer suppliers with transparent data. It reduces their own liability and administrative burden. When choosing between two similar devices, the one with clear, validated EUDAMED status and accessible vigilance history is the safer bet for a hospital risk manager. 

Interoperability and Digital Health 

High-quality UDI data in EUDAMED facilitates the integration of devices into electronic health records (EHRs) and hospital inventory systems. 

• Value-Added Services: Manufacturers can build value-added services around EUDAMED data, such as automated inventory replenishment for hospitals or digital tracking tools for implants. This turns a commodity device into a connected service, increasing customer stickiness. For example: 

• InVita Healthcare Technologies (UDITracker) & Terso Solutions combine UDI-specific tracking software with Radio-Frequency Identification (RFID) to manage tissue and implant supply chains bidirectionally. 

• RFID Discovery provides smart cabinets utilized in European hospitals that track UDI data to trigger automatic stock reordering and prevent the use of recalled or expired devices. 

• Real-World Evidence (RWE): By ensuring data consistency in EUDAMED, manufacturers make it easier to link their devices to clinical registries. This facilitates the collection of RWE, which is crucial for maintaining CE marking under the MDR/IVDR and for supporting reimbursement claims. The ability for such linkages has been demonstrated in examples such as the Coordinating Research & Evidence for Medical Devices (CORE-MD) project and orthopedic joint registries (e.g. Swedish Arthroplasty Register (SAR)). 

Mitigating Counterfeit Risks While Gaining EUDAMED Market Access

As illustrated by Europol’s recent Operation SHIELD VI (February 2026), which resulted in the seizure of 71,610 packages of medical devices, counterfeiting of medical devices continues to be a serious issue in the EU. A robust EUDAMED profile protects manufacturer branding. By publicly establishing the legitimate UDI-DIs and actor details, manufacturers make it harder for counterfeiters to pass off fake products. The public database becomes a verification tool for customers to authenticate the source of their devices. 

4. Being Prepared Before the Deadline 

With the functionality of the first four modules (Actor, UDI/Device, Notified Bodies & Certificates, Market Surveillance) officially declared, the countdown has begun. As stated above, the mandatory usage date is set for 28 May 2026. 

The Fallacy of “Wait and See” 

Many manufacturers have adopted a “wait and see” approach to compliance with the MDR/IVDR, delaying full implementation until the system is mandatory. This may be a dangerous strategic error for several reasons: 

• Volume Bottlenecks: As the deadline approaches, a rush of manufacturers will likely attempt to upload a significant volume of device records simultaneously. While the system’s data-handling capacity was verified during its independent IT audit, there are concerns regarding support capacity of the European Commission helpdesks and consultants during this time. 

• Data Gathering Time: Most manufacturers underestimate the state of their own data. Fields required by EUDAMED (e.g., EMDN codes, specific dimensions, storage conditions) may be missing from internal ERP systems or stored in unstructured PDFs. “Data gathering” is actually a significant “data remediation” project that can require significant time, particularly for manufacturers with sizeable product catalogs. 

• NB Capacity: NBs must also upload certificate data. If a manufacturer waits until the last minute, they may find their NB is too overwhelmed to validate their entries in time for the deadline. 

Strategic Phasing

Rather than treating EUDAMED compliance as a single deadline-driven task, manufacturers should approach it as a phased operational program. Breaking implementation into defined stages allows organizations to allocate resources efficiently, validate data integrity progressively, and reduce regulatory risk: 

• Phase 1 (Immediate): Actor Registration (SRN acquisition) and Basic UDI-DI architecture validation. 

• Phase 2 (Pre-Deadline): Uploading legacy device data and current MDR/IVDR portfolio. 

• Phase 3 (Post-Deadline): Maintenance and updates. Being prepared early allows a manufacturer to troubleshoot M2M (Machine-to-Machine) connections and XML upload errors without the pressure of a shipment stoppage. 

5. Why Would MedEnvoy Be Beneficial? 

For non-EU manufacturers, the EU Authorized Representative has always been a legal requirement. However, under the MDR/IVDR and EUDAMED, the role of the EU Authorized Representative has been given much more regulatory significance, sharing legal liability for defective devices on the same basis as, and jointly and severally with, the manufacturer (where the manufacturer has not complied with its obligations established under Article 10 of the MDR/IVDR). MedEnvoy has an established history of providing reliable, high-quality EU Authorized Representative services. 

Compliance Role Responsibilities  

In EUDAMED, the EU Authorized Representative has specific, hard-coded responsibilities. 

• Registration Verification: The EU Authorized Representative must verify the manufacturer’s registration and data in EUDAMED. If the EU Authorized Representative does not digitally verify the manufacturer’s data in the system, the manufacturer cannot obtain an SRN. Without an SRN, they cannot apply for conformity assessment (in the case of non-self-certified devices) or issue a complete Declaration of Conformity. 

• Liability and Due Diligence: The MDR holds the EU Authorized Representative jointly and severally liable for defective devices in certain scenarios. This liability drives experienced EU Authorized Representatives to be extremely thorough. They will not simply “rubber stamp” data; they will review it. 

Navigating the Technical Complexity of EUDAMED Market Access

An experienced EU Authorized Representative acts as an EU compliance navigator. 

• Regulatory Intelligence: MedEnvoy monitors EU regulatory changes and provides updates on these changes frequently, including changes related to EUDAMED. 

• Vigilance Management: The Vigilance module in EUDAMED will require precise reporting of adverse events. MedEnvoy knows exactly how to draft and submit a Manufacturer Incident Report (MIR) within the strict deadlines (15 days for serious incidents). Errors here can trigger immediate Competent Authority inspections. Such experience will keep manufacturers well served in the transition to vigilance reporting through EUDAMED. 

• Crisis Shield: In the event of a recall or Field Safety Corrective Action, the EU Authorized Representative is one of the primary points of contact for Competent Authorities. MedEnvoy knows how to manage these critical communications, ensuring that the manufacturer’s perspective is clearly conveyed and that regulatory actions are proportionate. 

Choosing a Strategic Partner, not a Vendor  

Low-cost, “mailbox” EU Authorized Representatives are a liability in the EUDAMED era. If they lack the technical staff to verify data or the legal expertise to manage liability, they may refuse to validate a manufacturer’s entry in EUDAMED out of fear, effectively blocking market access. On the other hand, they may overlook compliance gaps, exposing the manufacturer and themselves to administrative penalties / sanctions. An experienced partner, such as MedEnvoy, provides confidence and infrastructure to ensure smooth, continuous market access. 

Your EUDAMED Roadmap for EU Market Access

For manufacturers, the choice is clear: under-estimate EUDAMED preparations and risk market disruption; the alternate is solid preparation to ensure a smooth transition to the new paradigm. 

By recognizing the financial risks of non-compliance, leveraging data for faster market access, and partnering with a capable EU Authorized Representative, such as MedEnvoy, manufacturers can turn the EUDAMED challenge into a competitive advantage. The deadline of 28 May 2026 is not just a regulatory target; it is a business milestone. Those who are ready will find a European market that is more transparent, more efficient, and more open to their innovations. 

Strategic Action Plan for Manufacturers 

1. Audit Your Data Now: Do not assume your ERP data matches EUDAMED requirements. Perform a gap analysis against the latest EUDAMED requirements. 

2. Secure Your SRN: If you have not already registered as an Actor, do so immediately. 

3. Engage Your EU Authorized Representative: Open a dialogue with your EU Authorized Representative about EUDAMED readiness. 

4. Test the System: Utilize the EUDAMED “Playground” (test environment) to validate your XML uploads and M2M connections before the mandatory deadline. 

5. Educate Leadership: Ensure that leadership understands that EUDAMED is a market access issue, not just a database, to secure the necessary budget and resources. 

Learn more about EUDAMED Market Access with MedEnvoy 

This article a detailed overview of the business impact of EUDAMED being faced by manufacturers under the EU MDR / IVDR. MedEnvoy offers EU Authorized Representative and importer services. Please reach out if you require assistance by clicking here, and for more information about our consulting services, click here. Learn more about our MDRM service, where we handle both EUDAMED and swissdamed registration support.